Oncoparse opens AU$ 1.5 million pre-seed funding round for pancreatic cancer liquid biopsy development

PUBT · 2d ago
Oncoparse opens AU$ 1.5 million pre-seed funding round for pancreatic cancer liquid biopsy development
  • Oncoparse, a MedTech Actuator portfolio company, opened an AU$ 1.5 million pre-seed round to fund technology development.
  • Operations scaling planned, including a Melbourne laboratory expansion to increase scientific capacity.
  • Clinical validation anchored by PANDIAT with Epworth HealthCare, targeting 90 participants and about 720 samples across the care pathway.
  • Australian Genome Research Facility engaged to support production sequencing as Oncoparse prepares for its next growth phase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtech Actuator published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.